Skip to main content
OpenTrials
Completed

NCT Number: NCT06703970

Platelet Rich Plasma Versus Corticosteroids in Knee Osteoarthritis Pain

Prospective, multi-center, randomized trial comparing platelet rich plasma (PRP) versus corticosteroid injection for the treatment of symptoms of knee osteoarthritis. The purpose of the study is to determine which therapy provides a greater reduction in patient reported outcome measures of pain and function.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Knee Osteoarthritis (OA) Arthritis Joint Diseases Musculoskeletal Diseases Osteoarthritis Osteoarthritis, Knee Rheumatic Diseases

Age range

21 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sinai Hospital of Baltimore

Baltimore, Maryland, 21215, United States

About this study

Platelet rich plasma has become increasingly utilized as a treatment option for knee osteoarthritis. Corticosteroids is currently an approved medication to treat the symptoms of the knee osteoarthritis. There is limited evidence in a prospective randomized manner powered adequately to determine a difference between these treatments for pain associated with knee osteoarthritis.

Prospective, multi-center, single blind (participant), randomized trial comparing platelet rich plasma (PRP) versus corticosteroid injection for the treatment of symptoms of knee osteoarthritis. The purpose of the study is to determine which therapy provides a greater reduction in patient reported outcome measures of pain and function.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 21-80 years
  • Radiographic diagnosis of Kellgren-Lawrence (KL) grade of II or III knee osteoarthritis
  • Indicated for a knee injection to treat knee OA symptoms

Exclusion criteria

  • Any injections into the target knee within three months
  • Current overlying skin infection
  • Current or previous diagnosis of "chronic pain"
  • Opioid tolerant at time of screening (for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid.)
  • Allergy to any potential ingredients or medications utilized in any of the two groups
  • Treatment with another investigational drug or other intervention for pain
  • Diagnosis of Diabetes Mellitus
  • If female, pregnant or planning to be pregnant within the following 3 months or study duration
  • Any condition(s) or diagnosis, both physical or psychological, or physical exam finding in the opinion of the investigator that would precludes participation

Treatment and study plan

Corticosteroid injection

Drug

5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)

Platelet Rich Plasma Joint Injection

Device

~3 milliliters (mL) injection of autologous PRP Magellan Autologous Concentration System, ISTO Biologics

Primary outcomes

  1. Pain score VAS

    Time frame: Baseline, six weeks, and three months.

    Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10 cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be'). Pain intensity that is calculated by measuring the distance from the "no pain" end of a line to a mark placed by the patient to indicate their current pain level. This will be measured at baseline, six weeks, and three months.

Secondary outcomes

  1. Pain Score NRS

    Time frame: Baseline, six weeks, and three months.

    Numeric Pain Rating Scale (NRPS) where patients are asked to rate their pain on a scale of 0 to 10, with 0 representing "no pain" and 10 representing "the worst pain imaginable. This will be measured at baseline, six weeks, and three months.

  2. Functional score KOOS

    Time frame: Baseline, six weeks, and three months.

    Knee Injury and Osteoarthritis Outcome Score (KOOS) is a self-reported outcome measure assessing the patient's opinion about the health, symptoms, and functionality of their knee. It is a 42-item questionnaire, including 5 subscales: symptoms, pain, ADLs, sports/recreation, and quality of life. KOOS is used for any knee pathology and was found to be useful in assessing patients of various age populations, ranging from young to elderly adults. Scores range from 0 to 100 with a score of 0 indicating the worst possible knee symptoms and 100 indicating no knee symptoms. This will be measured at baseline, six weeks, and three months.

  3. Functional score WOMAC

    Time frame: Baseline, six weeks, and three months.

    The Western Ontario and McMaster Universities Arthritis Index (WOMAC) is widely used in the evaluation of Hip and Knee Osteoarthritis. It is a self-administered questionnaire consisting of 24 items divided into 3 subscales: Pain (5 items): during walking, using stairs, in bed, sitting or lying, and standing upright. The total WOMAC score is the sum of the three subscale scores, with a possible score range of 0-96. Higher scores indicate worse pain, stiffness, and functional limitations. This will be measured at baseline, six weeks, and three months.

  4. Pain Medication Adherence

    Time frame: Baseline through three months.

    Measured by number of days until pain medication (acetaminophen) is not adequate.

Sponsors and collaborators

Lead sponsor

LifeBridge Health

Other

Registry information

Official study title

The Efficacy of Platelet Rich Plasma Compared with Corticosteroid Injections for the Treatment of Pain Associated with Knee Osteoarthritis

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Nov 25, 2024
Registry last updated
Nov 25, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.